Identity
- Security key
- 18296
- Ticker
- MAIA
- Type
- CS — Common Stock
- Exchange
- NYSE American, LLC(XASE)
- Venue group
- NYSE
- Operating MIC
- XNYS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2022-07-28
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- MAIA
Detail
Enriched 2026-08-14 20:47
- Market cap
- $83,939,664.72
- Shares outstanding (class)
- 60,800,758
- Shares outstanding (weighted)
- 60,825,844
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 13
- Location
- CHICAGO, IL
- Homepage
- https://www.maiabiotech.com
- Description
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Market cap and share counts drift.